American International Group Inc. Invests $238,000 in Harrow Health, Inc. (NASDAQ:HROW)

American International Group Inc. purchased a new position in shares of Harrow Health, Inc. (NASDAQ:HROW) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,516 shares of the company’s stock, valued at approximately $238,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HROW. Braidwell LP bought a new position in shares of Harrow Health during the first quarter worth $30,736,000. Private Capital Management LLC bought a new position in shares of Harrow Health during the second quarter worth $7,253,000. Dimensional Fund Advisors LP boosted its position in shares of Harrow Health by 112.9% during the first quarter. Dimensional Fund Advisors LP now owns 442,455 shares of the company’s stock worth $9,362,000 after purchasing an additional 234,624 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Harrow Health by 117.5% during the first quarter. Two Sigma Advisers LP now owns 309,700 shares of the company’s stock worth $6,553,000 after purchasing an additional 167,300 shares in the last quarter. Finally, Stansberry Asset Management LLC bought a new stake in Harrow Health in the 4th quarter valued at $1,862,000. 75.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH boosted their price objective on shares of Harrow Health from $33.70 to $34.40 in a research report on Thursday, August 10th.

Insider Buying and Selling at Harrow Health

In other news, CEO Mark L. Baum acquired 7,500 shares of the stock in a transaction dated Thursday, November 16th. The shares were bought at an average cost of $8.11 per share, for a total transaction of $60,825.00. Following the purchase, the chief executive officer now directly owns 2,022,961 shares of the company’s stock, valued at $16,406,213.71. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Mark L. Baum acquired 7,500 shares of the stock in a transaction dated Thursday, November 16th. The shares were bought at an average cost of $8.11 per share, for a total transaction of $60,825.00. Following the purchase, the chief executive officer now directly owns 2,022,961 shares of the company’s stock, valued at $16,406,213.71. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Opaleye Management Inc. acquired 14,017 shares of the stock in a transaction dated Tuesday, September 19th. The shares were purchased at an average price of $14.65 per share, for a total transaction of $205,349.05. Following the completion of the purchase, the insider now directly owns 3,614,017 shares in the company, valued at $52,945,349.05. The disclosure for this purchase can be found here. Company insiders own 13.60% of the company’s stock.

Harrow Health Stock Up 5.6 %

Shares of HROW stock opened at $9.46 on Tuesday. The company has a current ratio of 5.80, a quick ratio of 2.25 and a debt-to-equity ratio of 2.42. Harrow Health, Inc. has a 1 year low of $7.60 and a 1 year high of $28.25. The firm’s fifty day moving average price is $13.73 and its two-hundred day moving average price is $17.41. The firm has a market capitalization of $332.22 million, a P/E ratio of -21.02 and a beta of 0.48.

Harrow Health (NASDAQ:HROW) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). Harrow Health had a negative net margin of 12.44% and a negative return on equity of 6.55%. The business had revenue of $34.27 million during the quarter, compared to analyst estimates of $37.58 million. During the same quarter in the previous year, the firm posted ($0.06) earnings per share. The firm’s quarterly revenue was up 50.1% on a year-over-year basis. On average, equities analysts predict that Harrow Health, Inc. will post -0.43 EPS for the current fiscal year.

About Harrow Health

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.